5

15

25

Claims

- 1. A pharmaceutical composition comprising a polytartrate polymer and at least one pharmaceutically active material characterised in that the composition is capable of releasing the pharmaceutically active material in a pulsatile manner and is obtainable by forming the tablet with a compression force between 10 and 65 kN/cm².
- 2. The composition according to claim 1 characterised in that the composition is formed at a compression force between 20 and 50 kN/cm².
- 10 3. The composition according to claim 1 or 2 characterised in that the polytartrate polymer forms degradation products that increase the pressure inside the composition.
 - 4. The composition according to claim 3 characterised in that the polytartrate polymer forms during degradation a C1 to C4 alcohol, aldehyde or ester or acetone.
 - The composition according to claim 4 characterised that the polytartrate polymer forms during degradation methanol, ethanol, propanol, isopropanol or acetone.
- 6. The composition according to claims 1 to 5 characterised in that the polytartrate polymer is selected from the group of polycondensates of dimethyl tartrate, diethyl tartrate, diisopropyl tartrate or copolymers thereof and 2,3-O-alkylidenetartaric acid derivatives.
 - 7. The composition according to claim 6 characterised in that the polytartrate polymer is 2 ' 3'- (1', 4'- diethyl) L- tartryl poly (2 , 3 -O-isopropylidene) -- L tartrate.
 - 8. The composition according to any of the claims 1 to 7 characterised in that the polytartrate polymer has a glass transition temperature that is greater than 40°C.
- 9. The composition according to any of the claims 1 to 8 characterised in that the pharmaceutically active material is selected from one or more of antigens, antibodies or pharmaceutical substances.
 - 10. The composition according to claim 9 characterised in that the pharmaceutically active material is a GnRH agonist.

20

- 11. The composition according to claim 10 characterised in that the pharmaceutically active material is buserelin.
- 12. The composition according to claim 11 characterised in that the pharmaceutically active material is azagly nafarelin.
- 5 13. The composition according to any of the claims 1 to 12 characterised in that the composition additionally comprises one or more of pharmaceutically acceptable excipients or adjuvants.
 - 14. Process for the preparation of a polytartrate composition according to claims 1 to 13 involving the steps of
- a) mixing an effective amount of a pharmaceutically active material with the polytartrate polymer,
 - b) shaping the mixture by a tabletting equipment to form compressed tablets by applying a compression force between 10 and 65kN/cm².
- 15. The process according to claim 14 characterised in that the pharmaceutically active material and the polytartrate polymer are mixed in a powdered form.
 - 16. The process according to any of the claims 14 or 15 characterised in that the mixture is sieved and optionally additional tabletting excipients are added to the mixture.